IGC Pharma, Inc. financial data

Symbol
IGC on NYSE
Location
Potomac, MD
Fiscal year end
31 December
Latest financial report
18 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 116% % -23%
Quick Ratio 52% % -10%
Debt-to-equity 29% % -24%
Return On Assets -73% % 39%
Operating Margin -732% % 7.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 98,796,089 shares
Common Stock, Shares, Outstanding 95,038,026 shares 22%
Entity Public Float $18,462,163 USD
Weighted Average Number of Shares Outstanding, Basic 90,457,910 shares 19%
Weighted Average Number of Shares Outstanding, Diluted 90,457,910 shares 19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,106,000 USD -6.5%
Cost of Revenue $595,000 USD 15%
Research and Development Expense $4,288,000 USD 20%
Operating Income (Loss) $8,094,000 USD 13%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $6,446,000 USD 49%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $6,447,000 USD 49%
Earnings Per Share, Basic -0.08 USD/shares 0%
Earnings Per Share, Diluted -0.08 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $900,000 USD 91%
Accounts Receivable, after Allowance for Credit Loss, Current $12,000 USD -76%
Inventory, Net $640,000 USD -55%
Other Assets, Current $124,000 USD -59%
Assets, Current $1,790,000 USD -41%
Property, Plant and Equipment, Net $2,141,000 USD -36%
Operating Lease, Right-of-Use Asset $11,000 USD -91%
Intangible Assets, Net (Excluding Goodwill) $5,101,000 USD 173%
Other Assets, Noncurrent $669,000 USD -1.8%
Assets $9,712,000 USD 7%
Accounts Payable, Current $1,014,000 USD 21%
Employee-related Liabilities, Current $407,000 USD -53%
Accrued Liabilities, Current $1,142,000 USD -37%
Liabilities, Current $2,156,000 USD -19%
Operating Lease, Liability, Noncurrent $2,000 USD -83%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $2,289,000 USD -19%
Common Stocks, Including Additional Paid in Capital $138,014,000 USD 6.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax $5,701,000 USD -65%
Retained Earnings (Accumulated Deficit) $124,890,000 USD -4.4%
Stockholders' Equity Attributable to Parent $7,423,000 USD 19%
Liabilities and Equity $9,712,000 USD 7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,407,000 USD 20%
Net Cash Provided by (Used in) Financing Activities $851,000 USD -66%
Net Cash Provided by (Used in) Investing Activities $580,000 USD
Common Stock, Shares Authorized 600,000,000 shares 300%
Common Stock, Shares, Issued 95,038,026 shares 22%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $49,000 USD -92%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $900,000 USD 91%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,000 USD 0%
Deferred Tax Assets, Valuation Allowance $20,753,000 USD
Deferred Tax Assets, Gross $20,753,000 USD
Operating Lease, Liability $11,000 USD
Depreciation $512,000 USD -11%
Payments to Acquire Property, Plant, and Equipment $8,000 USD -79%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $6,480,000 USD 48%
Property, Plant and Equipment, Gross $3,811,000 USD -36%
Operating Lease, Liability, Current $9,000 USD -93%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $9,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $14,000 USD -30%
Depreciation, Depletion and Amortization $141,000 USD -13%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $452,000 USD 12%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%